Literature DB >> 22050342

Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumors: profile report.

Lesley J Scott1, Victoria J Muir.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050342     DOI: 10.2165/11207650-000000000-00000

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


× No keyword cloud information.
  2 in total

1.  Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis.

Authors:  Qi Feng; Donglai Wang; Jiangang Feng; Peng Guo; Cuizhi Geng
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

2.  Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice.

Authors:  Hye-Rim Shin; Bong-Soo Kim; Hyun-Jung Kim; Heein Yoon; Woo-Jin Kim; Je-Yong Choi; Hyun-Mo Ryoo
Journal:  J Cell Physiol       Date:  2022-01-20       Impact factor: 6.513

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.